SU2C Scientific Advisors

Share this:
Email

Like this page on Facebook

Stand Up To Cancer’s Scientific Advisors ensure that your generous donations are being allocated to the most collaborative, innovative, and promising cancer research being done today. Our Advisors also oversee each grant recipient, to make sure that mandated research milestones are met, and that new treatments are on their way to our loved ones affected by cancer.

To learn more about out scientific advisors, please visit the links below.

Scientific Advisory Committee | Management Committee | Advocate Advisory Council | American Association for Cancer Research


Scientific Advisory Committee

Grants management and expert review for SU2C is conducted through the American Association for Cancer Research (AACR) via a rigorous, rapid and transparent process led by our “Blue Ribbon” Scientific Advisory Committee.


Chaired by Nobel Laureate Phillip A. Sharp, PhD, the Scientific Advisory Committee is comprised of highly accomplished scientists, physicians, and patient advocates, including:


Phillip A. Sharp, Ph. D., Chairperson, Institute Professor, MIT Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA

Arnold J. Levine, Ph.D., Vice Chairperson, Professor, Institute for Advanced Study, Princeton, NJ

William G. Nelson, M.D., Ph.D., Director, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD

Julian Adams, Ph.D., President of Research and Development, Infinity Pharmaceuticals, Inc., Cambridge, MA

Angelika Amon, Ph.D., Professor of Biology, MIT Koch Institute for Integrative Cancer Research, Massachussetts Institute Technology, Cambridge, MA

Kenneth C. Anderson, M.D., Kraft Family Professor of Medicine, Director, Lebow Institute for Myeloma Therapeutics, Jerome Lipper Multiple Myeloma Center, Dana-Farber Cancer Institute, Boston, MA

Frederick R. Appelbaum, M.D., Director, Clinical Research Division, Fred Hutchinson Cancer Research Center, Head, Division of Oncology, President, Seattle Cancer Care Alliance, University of Washington School of Medicine, Seattle, WA

Elizabeth H. Blackburn, Ph.D., Morris Herzstein, Professor, Department of Biochemistry and Biophysics University of California, San Francisco, San Francisco, CA

Richard B. Gaynor, M.D., Vice President, Clinical Development and Medical Affairs, Oncology Business Unit, Eli Lilly and Company, Indianapolis, IN

William N. Hait, M.D., Ph.D., Global Head, Janssen Research & Development, LLC, Raritan, NJ

Lee J. Helman, M.D., Scientific Director For Clinical Research, National Cancer Institute, National Institutes of Health, Bethesda, MD

Waun Ki Hong, M.D., Head, Division of Cancer Medicine, UT M.D. Anderson Cancer Center, Houston, TX

Carl H. June, M.D., Program Director of Translational Research, Abramson Family Cancer Research Institute, Abramson Cancer Center of University of Pennsylvania, Professor of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA

William G. Kaelin, Jr., M.D., Professor, Dana-Farber Cancer Institute, Boston, MA

Michael B. Kastan, M.D., Ph.D., Executive Director, Duke Cancer Institute, Durham, NC

Richard D. Kolodner, Ph.D., Professor of Medicine, University of California, San Diego Ludwig Institute for Cancer Research, La Jolla, CA

Guillermina (Gigi) Lozano, Ph.D., Chairman & Professor, Department of Genetics, UT MD Anderson Cancer Center, Houston, TX

Thomas J. Lynch, Jr., M.D., Director, Yale Cancer Center, Physician-in-Chief, Smillow Cancer Hospital at Yale-New Haven Hospital, Richard and Jonathan Sackler Professor of Internal Medicine, Yale University, New Haven, CT

Tak W. Mak, Ph.D., Director, Campbell Family Institute for Breast Cancer Research, Princess Margaret Hospital, Toronto, ON, Canada

Cecil B. Pickett, Ph.D., President, Research and Development (retired), Biogen Idec, Cambridge, MA

Nancy A. Roach*, Chair, Board of Directors, Fight Colorectal Cancer (Fight CRC), Hood River, OR

Laura K. Shawver, Ph.D., Chief Executive Officer, Cleave Biosciences, Burlingame, CA

Ellen V. Sigal, Ph.D.*, Chairperson and Founder, Friends of Cancer Research, Washington, DC

David A. Tuveson, M.D., Ph.D., Professor, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY

* Denotes Patient Advocate committee members selected by the SU2C Advocate Advisory Council



Management Committee

The Executive Management Committee (EMC) for SU2C serves an advisory role to the Executive Leadership Committee (ELC) to support them in their cancer research philanthropy, particularly in its scientific aspects, including: setting priorities, determining preferred funding models, identifying new opportunities and evaluating the success of the program. Committee members include noted leaders in clinical and translational cancer research, oncology and patient advocacy.

The six members of the Management Committee are:

John Glaspy, M.D., Chairperson, Professor of Medicine in the UCLA Dept of Medicine, Division of Hematology and Oncology

Andy Conrad, Ph.D, Director, Google

Sue Desmond-Hellman, M.D., M.P.H. (Emeritus), Chief Executive Officer, Bill & Melinda Gates Foundation

Raymond N. DuBois, M.D., Ph.D., Executive Director of the Biodesign Institute, Arizona State University

Kathy Giusti, co-founder of the Multiple Myeloma Research Foundation (MMRF) and former pharmaceutical industry executive

Lee Nadler, M.D., Virginia and D.K Ludwig Professor of Medicine
Dean for Clinical and Translational Research at Harvard Medical School, Director of Harvard Catalyst and SVP for Experimental Medicine at the Dana-Farber Cancer Institute



Advocate Advisory Council

SU2C’s Advocate Advisory Council is responsible for voicing the patient and family perspectives on cancer-related issues. To this end, the AAC elects representatives to sit on the Scientific Advisory Committee and recommends patient advocates for participation in both Dream Teams and the Innovative Research Grants. The Council includes:

Nancy Roach
Chairperson
C3: Colorectal Cancer Coalition
Alexandria, VA

Carolyn R. Aldigé
President and Founder
Prevent Cancer Foundation
Alexandria, VA

Laurie Fenton Ambrose
President and Chief Executive Officer
Lung Cancer Alliance
Washington, DC

Diane S. Blum
Executive Director
CancerCare
New York, NY

William P. Bro
Chief Executive Officer
Kidney Cancer Association
Evanston, IL

Christine Brunswick
Vice President
National Breast Cancer Coalition
Washington, DC

George Dahlman
Senior Vice President, Public Policy
Leukemia and Lymphoma Society
Alexandria, VA

Nancy Davenport Ennis
Founding Executive Director
Patient Advocate Foundation
Newport News, VA

Julie Fleshman
President and Chief Executive Officer
Pancreatic Cancer Action Network
El Segundo, CA

Kathy Giusti
Founder and Chief Executive Officer
Multiple Myeloma Research Foundation
Norwalk, CT

Ruth Hoffman
Executive Director
Candlelighters Childhood Cancer Foundation
Kensington, MD

Margaret C. Kirk
Chief Executive Officer
Breast Cancer Network of Strength
Chicago, IL

Thomas N. Kirk
President and Chief Executive Officer
UsTOO International
Downers Grove, IL

Hala Moddelmog
President
Susan G. Komen for the Cure
Dallas, TX

Susie Novis
President
International Myeloma Foundation
Los Angeles, CA

Catherine M. Poole
President and Founder
Melanoma International Foundation
Glenmoore, PA

Ellen Sigal
Chairperson and Founder
Friends of Cancer Research
Arlington, VA

Jonathan W. Simons
President and Chief Executive Officer
Prostate Cancer Foundation
Santa Monica, CA

Daniel E. Smith
President
American Cancer Society Cancer Action Network
Atlanta, GA

Kim Thiboldeaux
President and Chief Executive Officer
The Wellness Community
Washington, DC

Andrew Spiegel
Chief Executive Officer
Colon Cancer Alliance
Washington, DC

Doug Ulman
President
Lance Armstrong Foundation
Austin, TX

James E. Williams, Jr.
Chair-Elect
Intercultural Cancer Council
Camp Hill, PA



American Association for Cancer Research (AACR)

American Association for Cancer Research (AACR) The mission of the American Association for Cancer Research is to prevent and cure cancer. Founded in 1907, the AACR is the world’s oldest and largest professional organization dedicated to advancing cancer research. The membership includes 33,000 basic, translational and clinical researchers; health care professionals; and cancer survivors and advocates in the United States and more than 90 other countries. The AACR marshals the full spectrum of expertise from the cancer community to accelerate progress in the prevention, diagnosis and treatment of cancer through high-quality scientific and educational programs. It funds innovative, meritorious research grants, research fellowships and career development awards. The AACR Annual Meeting attracts more than 18,000 participants who share the latest discoveries and developments in the field. Special conferences throughout the year present novel data across a wide variety of topics in cancer research, treatment and patient care. Including Cancer Discovery, the AACR publishes seven major peer-reviewed journals: Cancer Research; Clinical Cancer Research; Molecular Cancer Therapeutics; Molecular Cancer Research; Cancer Epidemiology, Biomarkers & Prevention; and Cancer Prevention Research. AACR journals represented 20 percent of the market share of total citations in 2009. The AACR also publishes CR, a magazine for cancer survivors and their families, patient advocates, physicians and scientists.

American Association for Cancer Research (AACR)

Innovate Collaborate Accelerate
There are more than 200 different types of cancer.